First Selexis SUREtechnology Generated Antibody Approved for Market

09.01.2015 08:28

Selexis SA, a serial innovation company with proven technologies for characterized mammalian Research Cell Banks used for drug discovery to commercial manufacturing, announced today the first therapeutic biologic generated with the Selexis SUREtechnology Platform has been approved for market.

“This market approval represents a major milestone for Selexis,” said Dr. Igor Fisch, CEO, Selexis SA. “There are currently 56 clinical programs utilizing the SUREtechnology platform, including two Phase 3 programs. The increasing number of Selexis generated Research Cell Banks used in clinical programs, and now in a marketed product, is validation of our on-going scientific innovation and our commitment to delivering the highest quality work in biologic drug discovery and manufacturing.”

The Selexis SUREtechnology Platform is based on Selexis Genetic Elements — novel human DNA-based elements that control the dynamic organization of chromatin across mammalian cells. The Platform improves the way cells are used in the discovery, development and manufacturing of recombinant proteins.

The Selexis SURE CHO-M Cell Line is a proprietary high-performance mammalian cell line derived from CHO-K1 cells. It is used for the production of therapeutic recombinant proteins and monoclonal antibodies. Finally, growth and production properties of the Selexis SURE CHO-M Cell Line are well defined, and the feed strategy optimized allowing faster and more efficient scale-up into bioreactors.

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies for biologic drug discovery and mammalian Research Cell Banks for scale-up to manufacturing of recombinant therapeutic proteins. With the Company’s SUREtechnology Platform biopharmaceutical companies can significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for the production of monoclonal antibodies (MAbs) and other recombinant proteins including difficult-to-express proteins such as plasma proteins, GPCRs and non-natural proteins such as fusion proteins. Selexis generated cell lines are being used in a variety of programs from drug discovery to a commercial product.

Principal

Partners

Contributors